Revolution Medicines (RVMDW) Competitors $0.20 -0.01 (-6.76%) As of 08/25/2025 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock RVMDW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Revolution Medicines vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene 180 Life Sciences (NASDAQ:ATNFW) and Revolution Medicines (NASDAQ:RVMDW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Is ATNFW or RVMDW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Revolution Medicines N/A N/A N/A Which has higher valuation and earnings, ATNFW or RVMDW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ARevolution MedicinesN/AN/AN/AN/AN/A Does the media refer more to ATNFW or RVMDW? In the previous week, Revolution Medicines had 3 more articles in the media than 180 Life Sciences. MarketBeat recorded 3 mentions for Revolution Medicines and 0 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.00 beat Revolution Medicines' score of -0.54 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Neutral Revolution Medicines Negative Summary180 Life Sciences and Revolution Medicines tied by winning 1 of the 2 factors compared between the two stocks. Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMDW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVMDW vs. The Competition Export to ExcelMetricRevolution MedicinesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$137.79M$5.82B$9.74BDividend YieldN/A3.74%4.40%4.08%P/E RatioN/A3.8830.1425.84Price / SalesN/A4,065.08435.13105.64Price / CashN/A13.1925.7828.79Price / BookN/A47.799.425.99Net IncomeN/A-$90.99M$3.27B$265.29M7 Day Performance-4.76%6.93%3.64%4.07%1 Month Performance-23.08%8.89%3.52%0.93%1 Year PerformanceN/A204.23%29.95%18.21% Revolution Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVMDWRevolution MedicinesN/A$0.20-6.8%N/A+137.0%$0.00N/A0.00378ATNFW180 Life SciencesN/A$0.43-6.5%N/A+2,400.6%$0.00N/A0.007Gap DownHigh Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.11+20.0%N/A+104.8%$0.00$665.45K0.002Positive NewsGap UpDRTSWAlpha Tau MedicalN/A$0.27-1.1%N/A+20.8%$0.00N/A0.0080Positive NewsAPLMWApollomicsN/A$0.02-6.3%N/A+29.0%$0.00N/A0.0059Positive NewsBCTXWBriaCell TherapeuticsN/A$0.02flatN/A-93.3%$0.00N/A0.008Positive NewsCDIOWCardio DiagnosticsN/A$0.01+1.4%N/A-60.6%$0.00$19.90K0.007Positive NewsGap DownCELUWCelularityN/A$0.05+9.9%N/AN/A$0.00$54.22M0.00220Positive NewsGap DownHigh Trading VolumeCEROWCERo TherapeuticsN/A$0.02-3.6%N/AN/A$0.00N/A0.008Positive NewsGap DownCINGWCingulateN/A$0.05-22.8%N/A-21.8%$0.00N/A0.0020Positive NewsGap DownCLNNWCleneN/A$0.04+38.0%N/AN/A$0.00$350K0.00100Positive NewsGap Up Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Celularity Competitors CERo Therapeutics Competitors Cingulate Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVMDW) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access